Next
Prev
Groundbreaking results of a new Israeli clinical study
reveal that type 1 diabetes can be treated effectively and safely with
Alpha1-Antitrypsin (AAT), an anti-inflammatory protein that our body
normally generates when we’re sick.
“While looking for drugs to
cure diabetes, we sought a different path from available and
experimental treatments — one that tackled the problem, not merely the
symptom of dangerously high glucose levels,” prominent immunology
researcher Eli Lewis of Ben-Gurion University (BGU) of the Negev tells
ISRAEL21c.
He did the study in collaboration with the University
of Colorado’s Health Science Center, funded by Omni Bio. Type 1 diabetes
(also called juvenile diabetes) is characterized by difficulty
regulating blood-sugar levels because the hormone insulin – responsible
for distributing glucose to the body’s cells
for energy — either isn’t produced or does not get distributed because
of an abnormal autoimmune response.
To understand the “different
path” Lewis speaks of, one needs to understand that an adult pancreas
has approximately a million clusters of 3,000 to 4,000 hormone-producing
cells called islets of Langerhans. The predominant type of cell in
these islets is the beta cell, which senses when sugar is elevated in
the blood and releases insulin to remove glucose from the blood into the
peripheral tissues that then store it or break it down and convert it
into energy.
When the immune system mistakes beta cells for
“enemies” attacking the body, it destroys them. When two-thirds of the
islets are destroyed, the body no longer produces sufficient amounts of
insulin. This is called type 1 autoimmune diabetes, and requires
frequent checking of glucose levels and calculated doses of injected
insulin. Even with treatment, too-high
glucose levels are common.
Type 2 diabetes, on the other hand, is primarily metabolism-related and does not involve the immune system attacking islets.
According
to Lewis: “In 2002-3, one particularly exciting new treatment being
tested for type 1 diabetes was islet transplantation. And though the
results were impressive – removing patients’ need for insulin injections
altogether with perfectly normal blood glucose throughout their day —
there was a key problem with it. To prevent the immune system from
attacking any transplant, steroids were administered. But steroids
damage islets and are therefore contraindicated in this procedure.”
Lewis
and his team decided to look for another “safe and available” way to
address inflammation, while protecting islets from immune response and
focusing on approaches safe for children.
No comments:
Post a Comment